Liposomal mitoxantrone hydrochloride + cyclophosphamide + vincristine + etoposide + prednisone

Liposomal mitoxantrone hydrochloride + cyclophosphamide + vincristine + etoposide + prednisone is a multi-agent chemotherapy regimen, often referred to as the CMOEP regimen. It combines five agents: - Liposomal mitoxantrone hydrochloride (Lipo-MIT), an anthracycline-class antitumor agent formulated in liposomes for improved stability, controlled release, enhanced tumor targeting, and reduced cardiac toxicity compared to conventional anthracyclines. - Cyclophosphamide, an alkylating agent that crosslinks DNA and inhibits cell division. - Vincristine, a vinca alkaloid that disrupts microtubule formation and arrests cells in metaphase. - Etoposide, a topoisomerase II inhibitor causing DNA strand breaks. - Prednisone, a synthetic glucocorticoid with lympholytic effects. This combination is under investigation primarily for the treatment of untreated peripheral T-cell lymphoma (PTCL) and has shown promising efficacy with manageable safety profiles in early-phase clinical trials. The regimen aims to maximize anti-tumor activity by combining agents with complementary mechanisms of action[3].

Other names

CMOEP regimen